Related Experiment Video
Updated: Jun 8, 2026
06:40
Cost-Efficient Transcriptomic-Based Drug Screening
Published on: February 23, 2024
A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
Rodrigo Refoios Camejo1, Clare McGrath, Ron Herings
1Pfizer Inc., Surrey, UK. rodrigo.refoioscamejo@pfizer.com
Health Policy (Amsterdam, Netherlands)
|September 25, 2010
Summary
Arbitrary cost-effectiveness (CE) thresholds may hinder efficient drug research and development (R&D). Incorporating disease-specific factors into CE decision-making is crucial for fostering innovation and ensuring access to valuable treatments.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Innovation Studies
Background:
- Healthcare payers implement policies to optimize drug spending and achieve allocative efficiency.
- Cost-effectiveness (CE) thresholds link pharmaceutical prices to therapeutic value, defining acceptable incremental cost-effectiveness ratios (ICERs).
- Factors like increasing comparator effectiveness, decreasing drug prices, rising R&D costs, and shorter patent lives impact drug innovation.
Purpose of the Study:
- To analyze the impact of general cost-effectiveness thresholds on pharmaceutical R&D investment.
- To identify potential inefficiencies and lost clinical value resulting from arbitrary threshold policies.
- To propose adjustments to CE decision rules for better accommodation of innovation dynamics.
Main Methods:
- Economic modeling of drug R&D investment under varying market conditions and pricing regulations.
- Analysis of the relationship between R&D costs, patent exclusivity, and the establishment of CE thresholds.
- Simulation of innovation curves under different policy scenarios.
Main Results:
- A general, arbitrary CE threshold can disincentivize efficient R&D, leading to premature withdrawal of investment.
- Optimal innovation points may not be reached, potentially resulting in the loss of affordable, clinically effective treatments.
- The rate of R&D and innovation varies significantly across different disease areas.
Conclusions:
- Disease-specific characteristics must be considered in CE decision-making to accurately reflect innovation realities.
- Adopting a one-size-fits-all approach to CE thresholds can be detrimental to pharmaceutical innovation.
- Tailored CE policies are essential for balancing healthcare budgets with the need for novel drug development.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:21Pharmacodynamics: Overview and Principles
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...